GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...
The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...
GlobalData on MSN6d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
India has 29 states with at least 720 districts comprising of approximately 6 lakh villages, and over 8200 cities and towns. Indian postal department has allotted a unique postal code of pin code ...
The newly approved vaccine, known as Arexvy, represents an advance in preventive health measures, addressing a significant adult demographic at risk from RSV complications. With this approval, Canada ...
And to review, we now have three RSV vaccines that are FDA approved for adults, two protein subunit RSV vaccines, one by Pfizer called ABRYSVO that does not contain an adjuvant, and one by GSK called ...
US clinical-stage drug developer Acumen Pharmaceuticals (Nasdaq: ABOS) has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief ...
Results from the ARC-10 Phase III study of Arcus Biosciences (NYSE: RCUS) and Gilead Sciences’ (Nasdaq: GILD) domvanalimab and zimberelimab combination therapy indicate a significant reduction in ...
Teva Pharmaceutical Industries Ltd. ADR 1.52% $19.75B ...
IPC Indice de Precios Y Cotizaciones 51,449.43-395.74-0.76% ...
Most people have heard the term upper respiratory infection. It is often used interchangeably when describing a respiratory virus or the common cold. But do you know what a lower respiratory infection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback